Concord Medical (HKEX: 0370) has announced that his affiliated Hua Jian Medical cooperates with Renhe International, a complete arm of Renhe Pharmaceutical, to build a new Real-World assets (RWA) platform for over-the-counter (OTC) medicines.
The company is described as the first vertical RWA system dedicated to OTC medicines, with the aim of streamlining supply chains and improving transparency in China’s fast -growing OTC market.
OTC medicines tokenizing for safe, real-time trade
The project is still under development, but the companies said that the OTC pharmaceutical assets will look, making safe, traceable and real-time transactions between manufacturers, distributors and retailers possible.
By moving drug stocks and transactions to blockchain rails, the partners expect to lower inefficiencies, lower costs and improve compliance with regulatory standards, while market participants get more confidence in product authenticity.
Related: RWA sector has a record of $ 25 billion value, led by private credit and American treasury
Renhe’s role in technical infrastructure
Renhe International brings his background to digital transformation and blockchain acceptance for the initiative. The role is aimed at developing a scalable and safe technological infrastructure to support the platform.
Managers noted that the effort reflects the broader strategy of Hua Jian to combine healthcare and technology, in particular in the distribution layer where bottlenecks and fraud risks often occur.
Why the OTC market of China matters
The OTC market of China is expanding in both urban and rural areas, because self-care and preventive medicine get a grip. Data in the industry quoted by the companies suggest that this health care segment can become a large growth motor in the coming years.
By digitizing and tucking OTC drug flows, Hua Jian and Renhe want to accelerate distribution, improve responsiveness on demand shifts and reduce friction when supplying retail.
Implications in the industry
Analysts say that this partnership could become a model for integrating RWAS into pharmaceutical supply chains, a sector that is traditionally slow to adapt to digital innovation.
If successful, the framework can influence how OTC drugs are not only traded in China, but also on international care markets.
Related: RWA Crypto sector emerges as Day’s Top Performer with 6.9% profit
Safeguard: The information presented in this article is only for informative and educational purposes. The article does not constitute financial advice or advice of any kind. Coin Edition is not responsible for any losses as a result of the use of the aforementioned content, products or services. Readers are advised to be careful before taking action with regard to the company.